• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Research Data
  • Organizations
  • Researchers
  • More
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. CBA (4-chloro-2-(2-chlorophenoxy)acetamido) benzoic acid) inhibits TMEM206 mediated currents and TMEM206 does not contribute to acid-induced cell death in colorectal cancer cells
 

CBA (4-chloro-2-(2-chlorophenoxy)acetamido) benzoic acid) inhibits TMEM206 mediated currents and TMEM206 does not contribute to acid-induced cell death in colorectal cancer cells

Options
  • Details
  • Files
BORIS DOI
10.48350/194042
Official URL
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1369513/full
Publisher DOI
10.3389/fphar.2024.1369513
PubMed ID
38515848
Description
Introduction: Upon activation at low pH, TMEM206 conducts Cl− ions across plasma and vesicular membranes. In a (patho)physiological context, TMEM206 was reported to contribute to acid-induced cell death in neurons, kidney and cervical epithelial cells. We investigated the role of TMEM206 in acidinduced cell death in colorectal cancer cells. In addition, we studied CBA as a new small molecule inhibitor for TMEM206.
Methods: The role of TMEM206 in acid-induced cell death was studied with CRISPR/Cas9-mediated knockout and FACS analysis. The pharmacology of TMEM206 was determined with the patch clamp technique.
Results: In colorectal cancer cells, TMEM206 is not a critical mediator of acidinduced cell death. CBA is a small molecule inhibitor of TMEM206 (IC50 = 9.55 μM) at low pH, at pH 6.0 inhibition is limited.
Conclusion: CBA demonstrates effective and specific inhibition of TMEM206; however, its inhibitory efficacy is limited at pH 6.0. Despite this limitation, CBA is a potent inhibitor for functional studies at pH 4.5 and may be a promising scaffold for the development of future TMEM206 inhibitors.
Date of Publication
2024-03-07
Publication Type
article
Subject(s)
500 - Science::570 - Life sciences; biology
600 - Technology::610 - Medicine & health
500 - Science::540 - Chemistry
Language(s)
en
Contributor(s)
Kappel, Sven
Institut für Biochemie und Molekulare Medizin (IBMM)
IBMM Gruppe Peinelt
Melek, Korollusorcid-logo
Institut für Biochemie und Molekulare Medizin (IBMM)
IBMM Gruppe Peinelt
Ross-Kaschitza, Daniela
Institut für Biochemie und Molekulare Medizin (IBMM)
IBMM Gruppe Peinelt
Hauert, Barbara
Institut für Biochemie und Molekulare Medizin (IBMM)
IBMM Gruppe Peinelt
Gerber, Christian Elias
Institut für Biochemie und Molekulare Medizin (IBMM)
IBMM Gruppe Lochner
Lochner, Martinorcid-logo
Institut für Biochemie und Molekulare Medizin (IBMM)
IBMM Gruppe Lochner
Peinelt, Christine
Institut für Biochemie und Molekulare Medizin (IBMM)
IBMM Gruppe Peinelt
Additional Credits
Institut für Biochemie und Molekulare Medizin (IBMM)
Series
Frontiers in Pharmacology
Publisher
Frontiers
ISSN
1663-9812
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 4f1f0f [ 1.12. 12:07]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo